Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. - Wikidata - wikimedia - TriplyDB

Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.

Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.

http://www.wikidata.org/entity/Q37627154

about

The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression Persistent androgen receptor addiction in castration-resistant prostate cancer Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy.Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.Revisiting the role of antiandrogen strategies in ovarian cancer.BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype.Genistein up-regulates tumor suppressor microRNA-574-3p in prostate cancer.Difference in protein expression profile and chemotherapy drugs response of different progression stages of LNCaP sublines and other human prostate cancer cells Androgen receptor signaling in prostate cancer development and progression.Emerging targeted therapies for castration-resistant prostate cancer.Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation.Nuclear Kaiso indicates aggressive prostate cancers and promotes migration and invasiveness of prostate cancer cells.EGF Receptor Promotes Prostate Cancer Bone Metastasis by Downregulating miR-1 and Activating TWIST1.Oncogenic EGFR Represses the TET1 DNA Demethylase to Induce Silencing of Tumor Suppressors in Cancer Cells.Co-targeting EGFR and survivin with a bivalent aptamer-dual siRNA chimera effectively suppresses prostate cancer The osteoblastic and osteoclastic interactions in spinal metastases secondary to prostate cancer.AR-Signaling in Human Malignancies: Prostate Cancer and Beyond.Gαs protein expression is an independent predictor of recurrence in prostate cancer Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor.Targeting the relaxin hormonal pathway in prostate cancer.Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?HER2 and EGFR Overexpression Support Metastatic Progression of Prostate Cancer to Bone.Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.Screening and biological evaluation of myricetin as a multiple target inhibitor insulin, epidermal growth factor, and androgen receptor; in silico and in vitro.Hsp27 regulates EGF/β-catenin mediated epithelial to mesenchymal transition in prostate cancer.EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).Influence of peripheral whole-blood microRNA-7 and microRNA-221 high expression levels on the acquisition of castration-resistant prostate cancer: evidences from in vitro and in vivo studies.Investigational serine/threonine kinase inhibitors against prostate cancer metastases.Randomized Phase II trial of nintedanib, afatinib and sequential combination in castration-resistant prostate cancer.SPRY2 loss enhances ErbB trafficking and PI3K/AKT signalling to drive human and mouse prostate carcinogenesis MiR-146a suppresses tumor growth and progression by targeting EGFR pathway and in a p-ERK-dependent manner in castration-resistant prostate cancer.Loss of EGFR induced autophagy sensitizes hormone refractory prostate cancer cells to adriamycin.Androgen receptor expression on circulating tumor cells in metastatic breast cancer.Immunohistochemical expression of PDGFR, VEGF-C, and proteins of the mToR pathway before and after androgen deprivation therapy in prostate carcinoma: significant decrease after treatment.Combination of Carmustine and Selenite Inhibits EGFR Mediated Growth Signaling in Androgen-Independent Prostate Cancer Cells.Disruption of ETV6 leads to TWIST1-dependent progression and resistance to epidermal growth factor receptor tyrosine kinase inhibitors in prostate cancer.Multigene profiling of CTCs in mCRPC identifies a clinically relevant prognostic signature.Decline in Arylsulfatase B Expression Increases EGFR Expression by Inhibiting the Protein Tyrosine Phosphatase SHP2 and Activating JNK in Prostate Cells.Restoration of microRNA-130b expression suppresses osteosarcoma cell malignant behavior in vitro.

P2860

Q24564068-BA62A39F-2167-4D89-AF52-2587205C8464 Q26777163-8E65CDC1-5B2D-415E-BC08-2D3BD87CA593 Q28534382-A5D32338-B203-4EFA-A310-F35171397A40 Q33556178-ABF8BC58-3815-4D0F-A3FC-A3F70BE66A06 Q33977056-A13C22EF-A701-466B-9791-23DA47BB224F Q34219464-2AFFA91D-641D-40C3-AD2E-42497CB14D6B Q34581850-7F318E77-DF7F-4105-8643-661F2E68F03B Q34648583-EE16DC69-F78D-43A9-854C-99A4252DEC2F Q35070404-6DFF33F3-238D-46C9-ABC8-C46CBD76712B Q35183663-BBF70E01-6D86-4F1F-9A24-408EE407006B Q35999255-B37155BE-9A2B-4273-9FC3-E9799C342981 Q36068321-D0DEDF80-717C-496D-971B-FF8CE28E57E3 Q36355677-7E93ED39-A526-4E7E-8A54-FB6E699462D1 Q37007828-54CF69E7-1F56-41E8-B7DA-70CBE03B13A5 Q37095651-1418742D-06D9-4DC9-B49D-06C06E4739FC Q37125328-C25820DB-1C74-44D1-A21A-F167428D17B9 Q37615017-F738B116-20FD-4FAF-88C2-B6E813A0A56B Q37629545-F1496E90-FB34-4788-8204-65E01D74EBA4 Q37706058-D15ABF44-9313-4493-A68F-68F99837E4E3 Q38185175-5CF21F7D-758A-4087-8797-41A5504907A3 Q38231840-888981C2-1A8E-44A1-A1F1-5570140ABCE5 Q38571198-13510216-987F-4D2F-B311-703C2A99A784 Q38735527-66617E2F-CA9C-4CDF-9F35-DE4772E38959 Q38850154-EB05E16C-8469-467C-850B-2E5F5384BCD2 Q38884380-40971F0A-403A-4ED8-BB1D-046F6F031618 Q38965263-662C0A60-C126-4CE5-9876-51343BCF4D37 Q38989173-189882F5-DF3A-47B7-A18B-D40568FD75C6 Q39001625-79EDE944-9FD3-4F75-908D-7E4100197581 Q39021945-7D2CB4D3-4433-413E-97C7-DE41A03C2338 Q39257661-CEFEA5E1-C782-4F35-8FA8-C8C27FA42920 Q39339428-A228A684-DE56-4174-82F5-A0BE5F448AB9 Q39429436-8030A589-6433-409E-B536-F2815EC6DBF7 Q39527913-66C8E539-5621-4B9F-9072-6BF41897780A Q42366191-DE1B613A-4019-4A8A-B80D-CF69E4E585C3 Q43867243-257C69ED-A930-4E36-B36D-BC96888CAB58 Q48248291-E65EC375-186A-44AE-BA52-B0E05DB90D0A Q49887950-35FC50D6-FD9D-4E64-B99E-27491632FC5C Q49913687-98F6655E-770B-4917-92B6-E9513D412C6E Q54978374-009778B4-1A02-4857-BF73-8DAEE1E28A7F Q55381576-EE377CA3-7374-4EB6-9D24-84C42C7C8187

P2860

Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth.

http://www.wikidata.org/entity/Q37627154

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Epidermal growth factor recept ...... ular switch for tumour growth.

@en

Epidermal growth factor recept ...... ular switch for tumour growth.

@nl

type

label

Epidermal growth factor recept ...... ular switch for tumour growth.

@en

Epidermal growth factor recept ...... ular switch for tumour growth.

@nl

prefLabel

Epidermal growth factor recept ...... ular switch for tumour growth.

@en

Epidermal growth factor recept ...... ular switch for tumour growth.

@nl

P1433

Q37627154-422CCD4F-7B05-4E39-A37C-DD0054945ECE

P1476

Q37627154-2E2AD72F-9E2B-45D9-AFAB-9065B5325853

P2093

Q37627154-3D6C72CB-3A78-4830-AD10-FA575D02E3F7

Q37627154-C14EB802-F335-4297-BDDC-C891239FF799

P2860

Q37627154-0068CE52-62AC-4750-92C6-EE7899E72E6F

Q37627154-01B0EDDD-138B-493A-9B41-AAD3DDC734FC

Q37627154-027A78F0-06AD-4B0C-A453-E6ADBF468F19

Q37627154-04D66230-6FC1-4830-B052-C9CF7DB127D3

Q37627154-05DEAFA1-88B6-4F32-8A8C-4D79D52EF830

Q37627154-08020F31-F85D-48CB-997A-D63080915894

Q37627154-14E05804-F66B-4AB4-A242-9C928BFB7171

Q37627154-150BB649-7327-4E5C-9159-834080AF558B

Q37627154-1D9A59C7-3B79-4848-ABDC-D92E770143AA

Q37627154-1E44775D-835A-4284-B545-E94B202FAE7D

P2888

Q37627154-F5981CA9-AF7E-40AA-B68E-2AEBE4E22F9D

P304

Q37627154-01BEFD24-23B6-4DAA-B8DF-CCDD1A091BEA

P31

Q37627154-6B40950B-1151-479F-B673-DFFFE6BA7AAC

Q37627154-8DC2748E-009F-45E9-B625-C20322AE8384

P356

Q37627154-C13C6557-6839-4834-BBC5-950405F383A3

P407

Q37627154-2BBE5ACA-75DF-4F8B-9152-2197AE03E316

P433

Q37627154-EFC3F81E-0D1D-486D-9B2E-B03A5E2E3965

P478

Q37627154-03CFC78E-1781-4E52-847D-257D3DFB113F

P577

Q37627154-2184F58A-D6D1-4709-B2F6-466E4D93F03A

Q37627154-AFD86E48-082F-438F-BB18-85F582C27447

P5875

Q37627154-82945704-2AC7-4C05-AC5D-9AFB2EC80193

P6179

Q37627154-58CC6E6F-0226-4D77-8482-B9AE1A58D1F5

P698

Q37627154-A6135BC6-0862-4E41-A254-477668B53571

P921

Q37627154-0715A606-2CA2-4737-800F-F94B2FC0BAEF

Q37627154-135C3203-3817-46D0-9BD0-C4ACEF9400E4

Q37627154-D8B0477D-C528-49B8-A7F7-7EB10EC09271

Q37627154-DE3D2511-86D0-4566-9A82-DA52FC4BE2FE

Q37627154-ED686B33-2737-458A-885A-C04D68846AE8

P932

Q37627154-8F6371E6-5A1D-4433-BD3C-9B5FFAC6CBF4

P356

P1433

British Journal of Cancer

P1476

Epidermal growth factor recept ...... ular switch for tumour growth.

@en

P2093

A M Traish

http://www.w3.org/2001/XMLSchema#string

A Morgentaler

http://www.w3.org/2001/XMLSchema#string

P2860

Survival of cancer cells is maintained by EGFR independent of its kinase activity

The role of ephrins and Eph receptors in cancer

Increased prostate cell proliferation and loss of cell differentiation in mice lacking prostate epithelial androgen receptor

Disruption of prostate epithelial androgen receptor impedes prostate lobe-specific growth and function

Androgen receptor in prostate cancer

Androgen receptor mediates the reduced tumor growth, enhanced androgen responsiveness, and selected target gene transactivation in a human prostate cancer cell line.

EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR).

Shifting the paradigm of testosterone and prostate cancer: the saturation model and the limits of androgen-dependent growth.

Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk

Estrogen/EGF receptor interactions in breast cancer: rationale for new therapeutic combination strategies.

P2888

P304

1949-1956

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6605376

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2009-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38066019

http://www.w3.org/2001/XMLSchema#string

P6179

1003897368

http://www.w3.org/2001/XMLSchema#string

P698

19888222

http://www.w3.org/2001/XMLSchema#string

P921

prostate cancer

cell surface receptor

membrane proteins

P932

2795439

http://www.w3.org/2001/XMLSchema#string